QVA149 300/50 μg | Indacaterol 300 μg | Indacaterol 600 μg | Placebo | |
N=142 | N=140 | N=142 | N=140 | |
Least squares mean (SE) | ||||
Day 1 | ||||
Trough FVC (l) | 3.316 (0.021)* | 2.964 (0.021) | 2.978 (0.021) | 2.873 (0.021) |
Peak FEV1 | 1.659 (0.014)* | 1.567 (0.015) | 1.559 (0.014) | 1.423 (0.015) |
Standardised FEV1 AUC5min-4h | 1.576 (0.013)* | 1.487 (0.014) | 1.490 (0.013) | 1.345 (0.014) |
Standardised FEV1 AUC5min–23h 45min | 1.548 (0.012)* | 1.440 (0.012) | 1.444 (0.012) | 1.330 (0.012) |
Trough IC (l) | 2.180 (0.019)* † | 2.092 (0.019) | 2.102 (0.019) | 2.029 (0.019) |
Day 7 | ||||
Trough FVC (l) | 3.148 (0.023)* | 2.956 (0.024) | 2.968 (0.023) | 2.819 (0.024) |
Peak FEV1 | 1.709 (0.020)* | 1.579 (0.020) | 1.573 (0.020) | 1.394 (0.020) |
Standardised FEV1 AUC5min–4h | 1.641 (0.019)* | 1.505 (0.019) | 1.495 (0.019) | 1.320 (0.019) |
Standardised FEV1 AUC5min–12h | 1.610 (0.018)* | 1.473 (0.018) | 1.457 (0.018) | 1.317 (0.018) |
Standardised FEV1 AUC5min–23h 45 min | 1.569 (0.016)* | 1.438 (0.017) | 1.427 (0.017) | 1.302 (0.017) |
Trough IC (l) | 2.191 (0.021)* | 2.090 (0.022) | 2.073 (0.022) | 1.973 (0.022) |
↵* p<0.0001 for QVA149 300/50 μg versus placebo, indacaterol 300 μg and indacaterol 600 μg.
↵† p<0.01 for QVA149 300/50 μg versus indacaterol 300 μg and indacaterol 600 μg.
AUC, area under the curve; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacityl; IC, inspiratory capacity; mITT, modified intent-to-treat.